1
|
Colom-Cadena A, Martínez-Riveros H, Bordas A, Alonso-García L, Montoro-Fernández M, Romano-deGea P, Vidal-Alaball J, Solà-Segura E, Llibre JM, Revollo B, Casabona J, Agustí C. Corrigendum: Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees. Front Pediatr 2024; 11:1353806. [PMID: 38250593 PMCID: PMC10796811 DOI: 10.3389/fped.2023.1353806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Accepted: 12/13/2023] [Indexed: 01/23/2024] Open
Abstract
[This corrects the article DOI: 10.3389/fped.2022.975454.].
Collapse
Affiliation(s)
- Andreu Colom-Cadena
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Hector Martínez-Riveros
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
- Doctorate Program in Methodology of Biomedical Research and Public Health, Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine, Univ Autonòma de Barcelona, Badalona, Spain
| | - Anna Bordas
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Lucia Alonso-García
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Marcos Montoro-Fernández
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
| | - Pol Romano-deGea
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Josep Vidal-Alaball
- Health Promotion in Rural Areas Research Group, Gerència Territorial de la Catalunya Central, Institut Català de la Salut, Sant Fruitós del Bages, Spain
- Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol I Gurina, Sant Fruitós del Bages, Spain
- University of Vic-Central University of Catalonia, Vic, Spain
| | | | - Josep M. Llibre
- Division of Infectious Diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - Boris Revollo
- Division of Infectious Diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - Jordi Casabona
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut D’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
- Departament de Pediatria, D’Obstetrícia I Ginecologia I de Medicina Preventiva I de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Cristina Agustí
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Departament de Pediatria, D’Obstetrícia I Ginecologia I de Medicina Preventiva I de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain
| |
Collapse
|
2
|
Bernal S, Puertas MC, Morón-López S, Cranston RD, Urrea V, Dalmau J, Salgado M, Gálvez C, Erkizia I, McGowan I, Scherrer D, Revollo B, Sirera G, Santos JR, Clotet B, Paredes R, Martinez-Picado J. Impact of Obefazimod on Viral Persistence, Inflammation, and Immune Activation in People With Human Immunodeficiency Virus on Suppressive Antiretroviral Therapy. J Infect Dis 2023; 228:1280-1291. [PMID: 37395474 PMCID: PMC10629703 DOI: 10.1093/infdis/jiad251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 05/05/2023] [Accepted: 06/30/2023] [Indexed: 07/04/2023] Open
Abstract
BACKGROUND Persistence of viral reservoirs has been observed in people with human immunodeficiency virus (HIV), despite long-term antiretroviral therapy (ART), and likely contributes to chronic immune activation and inflammation. Obefazimod is a novel drug that inhibits human immunodeficiency virus type 1 (HIV-1) replication and reduces inflammation. Here we assess whether obefazimod is safe and might impact HIV-1 persistence, chronic immune activation, and inflammation in ART-suppressed people with HIV. METHODS We evaluated obefazimod-related adverse events, changes in cell-associated HIV-1 DNA and RNA, residual viremia, immunophenotype, and inflammation biomarkers in blood and rectal tissue. We compared 24 ART-suppressed people with HIV who received daily doses of 50 mg obefazimod for 12 weeks (n = 13) or 150 mg for 4 weeks (n = 11) and 12 HIV-negative individuals who received 50 mg for 4 weeks. RESULTS The 50- and 150-mg doses of obefazimod were safe, although the 150-mg dose showed inferior tolerability. The 150-mg dose reduced HIV-1 DNA (P = .008, median fold change = 0.6) and residual viremia in all individuals with detectable viremia at baseline. Furthermore, obefazimod upregulated miR-124 in all participants and reduced the activation markers CD38, HLA-DR, and PD-1 and several inflammation biomarkers. CONCLUSIONS The effect of obefazimod by reducing chronic immune activation and inflammation suggests a potential role for the drug in virus remission strategies involving other compounds that can activate immune cells, such as latency-reversing agents.
Collapse
Affiliation(s)
- Silvia Bernal
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Department of Infectious Diseases and Immunity, School of Medicine, University of Vic–Central University of Catalonia, Vic, Spain
| | - Maria C Puertas
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
| | - Sara Morón-López
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
| | - Ross D Cranston
- Department of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
| | - Víctor Urrea
- IrsiCaixa AIDS Research Institute, Badalona, Spain
| | | | - María Salgado
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Germans Trias i Pujol Research Institute, Badalona, Spain
| | | | | | - Ian McGowan
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | - Boris Revollo
- Fundació Lluita contra les Infeccions, Badalona, Spain
- Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Guillem Sirera
- Fundació Lluita contra les Infeccions, Badalona, Spain
- Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - José Ramón Santos
- Fundació Lluita contra les Infeccions, Badalona, Spain
- Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Department of Infectious Diseases and Immunity, School of Medicine, University of Vic–Central University of Catalonia, Vic, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Fundació Lluita contra les Infeccions, Badalona, Spain
- Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Roger Paredes
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Department of Infectious Diseases and Immunity, School of Medicine, University of Vic–Central University of Catalonia, Vic, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Fundació Lluita contra les Infeccions, Badalona, Spain
- Department of Infectious Diseases, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Javier Martinez-Picado
- IrsiCaixa AIDS Research Institute, Badalona, Spain
- Department of Infectious Diseases and Immunity, School of Medicine, University of Vic–Central University of Catalonia, Vic, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain
- Germans Trias i Pujol Research Institute, Badalona, Spain
- Catalan Institution for Research and Advanced Studies, Barcelona, Spain
| |
Collapse
|
3
|
Colom-Cadena A, Martínez-Riveros H, Bordas A, Alonso-García L, Montoro-Fernández M, Romano-deGea P, Vidal-Alaball J, Solà-Segura E, Llibre JM, Revollo B, Casabona J, Agustí C. Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees. Front Pediatr 2023; 10:975454. [PMID: 36741092 PMCID: PMC9891278 DOI: 10.3389/fped.2022.975454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 12/16/2022] [Indexed: 01/11/2023] Open
Abstract
Background SARS-CoV-2 screening is one of the pillars of non-pharmaceutical preventive strategies to early identify and isolate infected individuals and therefore decrease community incidence. Methods We assessed the feasibility of severe acute respiratory syndrome coronavirus 2 self-testing with antigen-detecting rapid diagnostic tests in attendees of educational settings. Results A total of 305 students (88.15%) and 41 staff (11.85%) from 9 to 56 years old participated in the self-testing procedure and answered the survey at the end of the study. 91.3% (n = 313) did not need help, 96.1% of participants reported the same outcome as the healthcare workers. 94.5% strongly or slightly agree with the statement "I would repeat the experience". Conclusion The study demonstrates that self-testing is acceptable and usable in children, adolescents and adults when the epidemiological situation may require a systematic screening of these populations, although supervision by health care or previously trained personnel is recommended for younger age groups.
Collapse
Affiliation(s)
- Andreu Colom-Cadena
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Héctor Martínez-Riveros
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
- Doctorate Program in Methodology of Biomedical Research and Public Health, Department of Pediatrics, Obstetrics and Gynecology and Preventive Medicine, Univ Autonòma de Barcelona, Badalona, Spain
| | - Anna Bordas
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Lucia Alonso-García
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Marcos Montoro-Fernández
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
| | - Pol Romano-deGea
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
| | - Josep Vidal-Alaball
- Health Promotion in Rural Areas Research Group, Gerència Territorial de la Catalunya Central, Institut Català de la Salut, Sant Fruitós del Bages, Spain
- Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol I Gurina, Sant Fruitós del Bages, Spain
- University of Vic-Central University of Catalonia, Vic, Spain
| | | | - Josep M. Llibre
- Division of Infectious Diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - Boris Revollo
- Division of Infectious Diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias I Pujol, Badalona, Spain
| | - Jordi Casabona
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Institut d’Investigació Germans Trias I Pujol (IGTP), Badalona, Spain
- Departament de Pediatria, d’Obstetrícia I Ginecologia I de Medicina Preventiva I de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain
- Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
| | - Cristina Agustí
- Centre of Epidemiological Studies on Sexually Transmitted Infections and AIDS of Catalonia (CEEISCAT), Ministry of Health, Government of Catalonia, Badalona, Spain
- Departament de Pediatria, d’Obstetrícia I Ginecologia I de Medicina Preventiva I de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain
| |
Collapse
|
4
|
Burgos J, Moreno-Fornés S, Reyes-Urueña J, Bruguera A, Martín-Iguacel R, Raventos B, Llibre JM, Imaz A, Peraire J, Orti AJ, Dalmau D, Casabona J, Miró JM, Falcó V, Esteve A, Fanjul F, Falcó V, Knobel H, Mallolas J, Tiraboschi J, Curran A, Burgos J, Revollo B, Gracia M, Gutierrez MDM, Murillas J, Homar F, Fernández-Montero JV, González E, Peraire J, Force L, Leon E, Hortos M, Vilaró I, Orti A, Dalmau D, Jaen À, Lazzari ED, Berrocal L, Rodríguez L, Gargoulas F, Vanrell T, Carlos J, Vilà J, Martínez M, Morell B, Tamayo M, Palacio J, Ambrosioni J, Laguno M, Martínez-Rebollar M, Blanco JL, Garcia F, Torres B, Mora LDL, Inciarte A, Ugarte A, Chivite I, González-Cordon A, Leal L, Jou A, Negredo E, Saumoy M, Silva A, Scévola S, Suanzes P, Alvarez P, Mur I, Jaume MR, García-Gasalla M, Ribas MÀ, Campins AA, Peñaranda M, Martin ML, Haydee H, Calzado S, Cervantes M, Navarro M, Payeras A, Cifuentes C, Villoslada A, Sorní P, Molero M, Abdulghani N, Comella T, Sola R, Vargas M, Viladés C, Martí A, Yeregui E, Rull A, Barrufet P, Arbones L, Chamarro E, Escrig C, Cairó M, Martinez-Lacasa X, Font R, Macorigh L, Hernández J. Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens. J Antimicrob Chemother 2022; 78:108-116. [PMID: 36308326 DOI: 10.1093/jac/dkac361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Accepted: 10/05/2022] [Indexed: 12/27/2022] Open
Abstract
OBJECTIVES To assess the clinical and immunovirological outcomes among naive patients with advanced HIV presentation starting an antiretroviral regimen in real-life settings. METHODS This was a multicentre, prospective cohort study. We included all treatment-naive adults with advanced HIV disease (CD4+ T cell count < 200 cells/mm3or presence of an AIDS-defining illness) who started therapy between 2010 and 2020. The main outcomes were mortality, virological effectiveness (percentage of patients with viral load of ≤50 copies/mL) and immune restoration (percentage of patients with CD4+ T cell count above 350 cells/mm3). Competing risk analysis and Cox proportional models were performed. A propensity score-matching procedure was applied to assess the impact of the antiretroviral regimen. RESULTS We included 1594 patients with advanced HIV disease [median CD4+T cell count of 81 cells/mm3and 371 (23.3%) with AIDS-defining illness] and with a median follow-up of 4.44 years. The most common ART used was an integrase strand transfer inhibitor (InSTI) regimen (46.9%), followed by PI (35.7%) and NNRTI (17.4%), with adjusted mortality rates at 3 years of 3.1% (95% CI 1.8%-4.3%), 4.7% (95% CI 2.2%-7.1%) and 7.6% (95% CI 5.4%-9.7%) (P = 0.001), respectively. Factors associated with increased mortality included older age and history of injection drug use, whilst treatment with an InSTI regimen was a protective factor [HR 0.5 (95% CI 0.3-0.9)]. A sensitivity analysis with propensity score procedure confirms these results. Patients who started an InSTI achieved viral suppression and CD4+ T cell count above 350 cells/mm3significantly earlier. CONCLUSIONS In this large real-life prospective cohort study, a significant lower mortality, earlier viral suppression and earlier immune reconstitution were observed among patients with advanced HIV disease treated with InSTIs.
Collapse
Affiliation(s)
- Joaquin Burgos
- Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Sergio Moreno-Fornés
- Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona, Spain.,Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain
| | - Juliana Reyes-Urueña
- Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona, Spain.,Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.,CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| | - Andreu Bruguera
- Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona, Spain
| | - Raquel Martín-Iguacel
- Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona, Spain.,Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
| | - Berta Raventos
- Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | - Josep M Llibre
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Arkaitz Imaz
- Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, L'Hospitales de Llobregat, Spain
| | - Joaquim Peraire
- Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitaria Pere Virgili (IISPV), Tarragona, Spain
| | | | - David Dalmau
- Hospital Universitari MutuaTerrassa, Terrassa, University of Barcelona (Catalonia), Spain
| | - Jordi Casabona
- Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona, Spain.,Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.,Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Josep M Miró
- Infectious Diseases Clínic. Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.,CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain
| | - Vicenç Falcó
- Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Vall d'Hebron Research Institute (VHIR), Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Llibre JM, Revollo B, Aguilar S, Calomarde-Gomez C, Bruguera A, Martin-Iguacel R. Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19. J Infect Dis 2022; 226:938-940. [PMID: 35763360 PMCID: PMC9278196 DOI: 10.1093/infdis/jiac256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 06/24/2022] [Indexed: 11/17/2022] Open
Affiliation(s)
- Josep M Llibre
- Infectious Diseases Division, University Hospital Germans Trias, Badalona, Spain.,Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
| | - Boris Revollo
- Infectious Diseases Division, University Hospital Germans Trias, Badalona, Spain.,Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
| | - Sergi Aguilar
- Internal Medicine, University Hospital Germans Trias, Badalona, Spain
| | | | - Andreu Bruguera
- Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain
| | - Raquel Martin-Iguacel
- Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain.,Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
| |
Collapse
|
6
|
Llibre JM, Martin-Iguacel R, Revollo B. Practical measures for SARS-CoV-2 infection prevention – Authors' reply. The Lancet Infectious Diseases 2022; 22:21. [PMID: 34953549 PMCID: PMC8694749 DOI: 10.1016/s1473-3099(21)00766-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 11/24/2021] [Indexed: 10/25/2022]
|
7
|
Affiliation(s)
- Josep M Llibre
- Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Sebastià Videla
- Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, and Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), and University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Bonaventura Clotet
- Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain
| | - Boris Revollo
- Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
8
|
Nacarapa E, Verdu ME, Nacarapa J, Macuacua A, Chongo B, Osorio D, Munyangaju I, Mugabe D, Paredes R, Chamarro A, Revollo B, Alexandre SS, Simango M, Torrus D, Ramos-Rincon JM. Predictors of attrition among adults in a rural HIV clinic in southern Mozambique: 18-year retrospective study. Sci Rep 2021; 11:17897. [PMID: 34504234 PMCID: PMC8429703 DOI: 10.1038/s41598-021-97466-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 08/18/2021] [Indexed: 11/09/2022] Open
Abstract
HIV remains a major cause of morbidity and mortality for people living in many low-income countries. With an HIV prevalence of 12.4% among people aged over 15 years, Mozambique was ranked in 2019 as one of eight countries with the highest HIV rates in the world. We analyzed routinely collected data from electronical medical records in HIV-infected patients aged 15 years or older and enrolled at Carmelo Hospital of Chokwe in Chokwe from 2002 to 2019. Attrition was defined as individuals who were either reported dead or lost to follow-up (LTFU) (≥ 90 days since the last clinic visit with missed medical pick-up after 3 days of failed calls). Kaplan–Meier survival curves and Cox regression analyses were used to model the incidence and predictors of time to attrition. From January 2002 to December 2019, 16,321 patients were enrolled on antiretroviral therapy (ART): 59.2% were women, and 37.9% were aged 25–34 years old. At the time of the analysis, 7279 (44.6%) were active and on ART. Overall, the 16,321 adults on ART contributed a total of 72,987 person-years of observation. The overall attrition rate was 9.46 per 100 person-years. Cox regression showed a higher risk of attrition in those following an inpatient regimen (hazard ratio [HR] 3.18, 95% confidence interval [CI] 2.89–3.50; p < 0.001), having CD4 counts under 50 cells/µL (HR 1.91, 95% CI 1.63–2.24, p < 0.001), receiving anti-TB treatment within 90 days of ART initiation (HR 6.53, 95% CI 5.72–7.45; p < 0.001), classified as WHO clinical stage III (HR 3.75, 95% CI 3.21–4.37; p < 0.001), and having Kaposi’s sarcoma (HR 1.99, 95% CI 1.65–2.39, p < 0.001). Kaplan–Meier analysis showed that patients with CD4 counts of less than 50 cells/µL on ART initiation had a 40% lower chance of survival at 18 years. Low CD4 cell counts, ART initiation as an inpatient, WHO clinical stage III, and anti-tuberculosis treatment within 90 days of ART initiation were strongly associated with attrition. Strengthening HIV testing and ART treatment, improving the diagnosis of tuberculosis before ART initiation, and guaranteed psychosocial support systems are the best tools to reduce patient attrition after starting ART.
Collapse
Affiliation(s)
- Edy Nacarapa
- Carmelo Hospital of Chókwè - The Daughters of Charity, Saint Vicente of Paul, TB/HIV Division, Avenida Trabalho, Chokwé, Gaza Province, Mozambique.,Tinpswalo Association, Vincentian Association to Fight AIDS and TB, Research Unit, Chókwè, Gaza Province, Mozambique
| | - M Elisa Verdu
- Carmelo Hospital of Chókwè - The Daughters of Charity, Saint Vicente of Paul, TB/HIV Division, Avenida Trabalho, Chokwé, Gaza Province, Mozambique
| | - Joana Nacarapa
- Carmelo Hospital of Chókwè - The Daughters of Charity, Saint Vicente of Paul, TB/HIV Division, Avenida Trabalho, Chokwé, Gaza Province, Mozambique.,Tinpswalo Association, Vincentian Association to Fight AIDS and TB, Research Unit, Chókwè, Gaza Province, Mozambique
| | - Artur Macuacua
- Carmelo Hospital of Chókwè - The Daughters of Charity, Saint Vicente of Paul, TB/HIV Division, Avenida Trabalho, Chokwé, Gaza Province, Mozambique
| | - Bartolomeu Chongo
- Carmelo Hospital of Chókwè - The Daughters of Charity, Saint Vicente of Paul, TB/HIV Division, Avenida Trabalho, Chokwé, Gaza Province, Mozambique
| | | | - Isabelle Munyangaju
- Tinpswalo Association, Vincentian Association to Fight AIDS and TB, Research Unit, Chókwè, Gaza Province, Mozambique
| | | | - Roger Paredes
- IrsiCaixa - Institute of AIDS Research, Barcelona, Spain.,FLS Foundation - Fight AIDS Foundation, Barcelona, Spain
| | - Ana Chamarro
- FLS Foundation - Fight AIDS Foundation, Barcelona, Spain
| | - Boris Revollo
- FLS Foundation - Fight AIDS Foundation, Barcelona, Spain
| | | | | | - Diego Torrus
- Department of Internal Medicine, University General Hospital of Alicante and Miguel Hernandez University, Elche, Spain
| | - Jose-Manuel Ramos-Rincon
- Department of Internal Medicine, University General Hospital of Alicante and Miguel Hernandez University, Elche, Spain.
| |
Collapse
|
9
|
López Seguí F, Navarrete Duran JM, Tuldrà A, Sarquella M, Revollo B, Llibre JM, Ara del Rey J, Estrada Cuxart O, Paredes Deirós R, Hernández Guillamet G, Clotet Sala B, Vidal Alaball J, Such Faro P. Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings. Int J Environ Res Public Health 2021; 18:7129. [PMID: 34281065 PMCID: PMC8297152 DOI: 10.3390/ijerph18137129] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 06/25/2021] [Accepted: 06/26/2021] [Indexed: 12/20/2022]
Abstract
Background: The epidemiological situation generated by COVID-19 has cast into sharp relief the delicate balance between public health priorities and the economy, with businesses obliged to toe the line between employee health and continued production. In an effort to detect as many cases as possible, isolate contacts, cut transmission chains, and limit the spread of the virus in the workplace, mass testing strategies have been implemented in both public health and industrial contexts to minimize the risk of disruption in activity. Objective: To evaluate the economic impact of the mass workplace testing strategy as carried out by a large automotive company in Catalonia in terms of health and healthcare resource savings. Methodology: Analysis of health costs and impacts based on the estimation of the mortality and morbidity avoided because of screening, and the resulting savings in healthcare costs. Results: The economic impact of the mass workplace testing strategies (using both PCR and RAT tests) was approximately €10.44 per test performed or €5575.49 per positive detected; 38% of this figure corresponds to savings derived from better use of health resources (hospital beds, ICU beds, and follow-up of infected cases), while the remaining 62% corresponds to improved health rates due to the avoided morbidity and mortality. In scenarios with higher positivity rates and a greater impact of the infection on health and the use of health resources, these results could be up to ten times higher (€130.24 per test performed or €69,565.59 per positive detected). Conclusion: In the context of COVID-19, preventive actions carried out by the private sector to safeguard industrial production also have concomitant public benefits in the form of savings in healthcare costs. Thus, governmental bodies need to recognize the value of implementing such strategies in private settings and facilitate them through, for example, subsidies.
Collapse
Affiliation(s)
- Francesc López Seguí
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
- North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08916 Badalona, Spain; (J.A.d.R.); (O.E.C.)
| | - Jose Maria Navarrete Duran
- Health Safety and Emergencies Unit SEAT CUPRA, the Companies of the Volkswagen Group in Spain, 08916 Badalona, Spain;
| | - Albert Tuldrà
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Maria Sarquella
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Boris Revollo
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Josep Maria Llibre
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Jordi Ara del Rey
- North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08916 Badalona, Spain; (J.A.d.R.); (O.E.C.)
| | - Oriol Estrada Cuxart
- North Metropolitan Primary Care Directorate, Catalan Institute of Health, 08916 Badalona, Spain; (J.A.d.R.); (O.E.C.)
| | - Roger Paredes Deirós
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Guillem Hernández Guillamet
- Central Catalonia Primary Care Directorate, Catalan Institute of Health, Sant Fruitos de Bages, 08272 Barcelona, Spain; (G.H.G.); (J.V.A.)
| | - Bonaventura Clotet Sala
- Fight AIDS and Infectious Diseases Foundation, 08916 Badalona, Spain; (A.T.); (M.S.); (B.R.); (J.M.L.); (R.P.D.); (B.C.S.)
| | - Josep Vidal Alaball
- Central Catalonia Primary Care Directorate, Catalan Institute of Health, Sant Fruitos de Bages, 08272 Barcelona, Spain; (G.H.G.); (J.V.A.)
- Health Promotion in Rural Areas Research Group, Gerencia Territorial de la Catalunya Central, Institut Catala de la Salut, Sant Fruitos de Bages, 08272 Barcelona, Spain
- Unitat de Suport a la Recerca de la Catalunya Central, Fundacio Institut Universitari per a la Recerca a l’Atencio Primaria de Salut Jordi Gol i Gurina, Sant Fruitos de Bages, 08272 Barcelona, Spain
| | - Patricia Such Faro
- Health Safety and Emergencies Unit SEAT CUPRA, the Companies of the Volkswagen Group in Spain, 08916 Badalona, Spain;
| |
Collapse
|
10
|
Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, Podzamczer D, Manzano JL, Molto J, Revollo B, Carrera C, Mateu L, Fancelli S, Espinosa E, Clotet B, Martinez-Picado J, Cerezuela P, Soria A, Marquez I, Mandala M, Berrocal A. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer 2021; 9:jitc-2020-001664. [PMID: 33782108 PMCID: PMC8009216 DOI: 10.1136/jitc-2020-001664] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/31/2021] [Indexed: 01/11/2023] Open
Abstract
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.
Collapse
Affiliation(s)
- Maria Gonzalez-Cao
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain
| | - Teresa Puertolas
- Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain
| | - Mar Riveiro
- Liver Unit, Department of Internal Medicine, Vall d'Hebron Hospital Universitari, Barcelona, Catalunya, Spain
| | - Eva Muñoz-Couselo
- Oncology Department, Vall d'Hebron Hospital Universitari, Barcelona, Catalunya, Spain
| | - Carolina Ortiz
- Oncology Department, Vall d'Hebron Hospital Universitari, Barcelona, Catalunya, Spain
| | - Roger Paredes
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
| | - Daniel Podzamczer
- Department of Infectious Diseases, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Catalunya, Spain
| | - Jose Luis Manzano
- Oncology Department, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Jose Molto
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
| | - Boris Revollo
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
| | - Cristina Carrera
- Dermatology Department, Melanoma Group IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
| | - Lourdes Mateu
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
| | - Sara Fancelli
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain.,Oncology Department, Azienda Ospedaliero Careggi, Firenze, Toscana, Italy
| | - Enrique Espinosa
- Oncology Department, Hospital Universitario La Paz, Madrid, Spain
| | - Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
| | - Javier Martinez-Picado
- IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain.,Catalan Institution for Research and Advanced Studies (ICREA), Catalan Institution for Research and Advanced Studies, Barcelona, Catalunya, Spain
| | - Pablo Cerezuela
- Oncology Department, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - Ainara Soria
- Oncology Department, Hospital Ramon y Cajal, Madrid, Spain
| | - Ivan Marquez
- Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Mario Mandala
- Oncology Department, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - Alfonso Berrocal
- Oncology Department, Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain
| | | |
Collapse
|
11
|
Revollo B, Videla S, Llibre JM, Paredes R, Piñol M, García-Cuyàs F, Ornelas A, Puig J, Parés D, Corral J, Clotet B, Sirera G. Routine Screening of Anal Cytology in Persons With Human Immunodeficiency Virus and the Impact on Invasive Anal Cancer: A Prospective Cohort Study. Clin Infect Dis 2021; 71:390-399. [PMID: 31504329 DOI: 10.1093/cid/ciz831] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 08/24/2019] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND The efficacy of screening programs to prevent anal cancer in persons with human immunodeficiency virus 1 (HIV-1) is unclear. METHODS To examine the impact of a screening program to detect anal cancer precursors on the incidence of cases of invasive anal squamous-cell carcinoma (IASCC) in persons with HIV-1, we performed a single-center, retrospective analysis of a prospective cohort of outpatients with HIV-1 attending a reference HIV unit from January 2005 onward. All participants were invited to participate in a continued structured screening program for anal cancer prevention. We estimated the incidence of IASCC and performed a comparative analysis between subjects enrolled in the screening program (screening group) and those who declined to participate (nonscreening group). To reduce any selection bias, a propensity score analysis was applied. RESULTS We included 3111 persons with HIV-1 (1596 men-who-have-sex-with-men [MSM], 888 men-who-have-sex-with-women [MSW], 627 women; mean age, 41 years), with a median follow-up of 4.7 years (14 595 patient-years of follow-up); 1691 (54%) participated in the screening program. Ten patients were diagnosed with IASCC: 2 (MSM) in the screening group and 8 (4 MSM, 2 MSW, and 2 women) in the nonscreening group. The incidence rates of IASCC were 21.9 (95% confidence interval [CI], 2.7-70.3) and 107.0 (95% CI, 46.2-202.0) per 100 000 person-years, respectively. After a propensity score adjustment, the difference was significant in favor of the screening group (hazard ratio, 0.17; 95% CI, .03-.86). CONCLUSIONS The number of cases of IASCC was significantly lower in persons with HIV engaged in an anal cytology screening program. These results should be validated in a randomized clinical trial.
Collapse
Affiliation(s)
- Boris Revollo
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Department of Medicine, Autonomous University of Barcelona, Catalonia, Spain.,Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Sebastián Videla
- Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet de Llobregat, Barcelona
| | - Josep M Llibre
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Roger Paredes
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet de Llobregat, Barcelona.,IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain
| | - Marta Piñol
- Department of Surgery, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Francesc García-Cuyàs
- Department of Surgery, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Arelly Ornelas
- Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Jordi Puig
- Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - David Parés
- Department of Surgery, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Javier Corral
- Department of Surgery, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| | - Bonaventura Clotet
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain.,Universitat de Vic-UCC, Vic, Catalonia, Spain
| | - Guillem Sirera
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain.,Fight AIDS Foundation, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
| |
Collapse
|
12
|
Corral J, Parés D, García-Cuyás F, Revollo B, Chamorro A, Lecumberri C, Tarrats A, Castella E, Piñol M, Clotet B, Videla S, Sirera G. Incidence of Recurrent High-Grade Anal Dysplasia in HIV-1-Infected Men and Women Following Infrared Coagulation Ablation: A Retrospective Cohort Study. Pathogens 2021; 10:pathogens10020208. [PMID: 33672969 PMCID: PMC7918241 DOI: 10.3390/pathogens10020208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 02/10/2021] [Accepted: 02/12/2021] [Indexed: 11/18/2022] Open
Abstract
This single-center, retrospective cohort study sought to estimate the cumulative incidence in HIV-1-infected patients of biopsy-proven high-grade anal intraepithelial neoplasia (HGAIN) recurrence after infrared coagulation (IRC) treatment. The study was based on data from a prospectively compiled database of 665 HIV-1-infected outpatients who attended a hospital Clinical Proctology/HIV Unit between January 2012 and December 2015. Patient records were checked to see which ones had received IRC treatment but later experienced a recurrence of HGAIN. Cytology samples were also checked for the presence of human papilloma virus (HPV). A total of 81 of the 665 patients (12%, 95%CI: 10–15%), of whom 65 were men and 16 women, were diagnosed with HGAIN and again treated with IRC. Of these 81, 20 (25%) experienced recurrent HGAIN, this incidence being true of both men (16/65, 95%CI: 19–57%) and women (4/16, 95%CI: 10–50%). The median time to recurrence was 6 (2–19) months overall, 6 (2–19) months in men, and 4 (2–6) months in women. HPV infection was detected in all patients except two, with HPV-16 being the most common genotype. This rate of incidence of recurrent HGAIN following IRC treatment is consistent with other reports and highlights the importance of continued post-treatment surveillance, particularly in the first year.
Collapse
Affiliation(s)
- Javier Corral
- Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (D.P.); (F.G.-C.); (M.P.)
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- School of Medicine, Universitat Autónoma de Barcelona (UAB), Edifici M, Av. de Can Domènech, Bellaterra, 08193 Barcelona, Spain
- Correspondence: (J.C.); (S.V.)
| | - David Parés
- Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (D.P.); (F.G.-C.); (M.P.)
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- School of Medicine, Universitat Autónoma de Barcelona (UAB), Edifici M, Av. de Can Domènech, Bellaterra, 08193 Barcelona, Spain
| | - Francesc García-Cuyás
- Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (D.P.); (F.G.-C.); (M.P.)
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
| | - Boris Revollo
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| | - Ana Chamorro
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| | - Carla Lecumberri
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- Department of Obstetrics and Gynaecology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| | - Antoni Tarrats
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- Department of Obstetrics and Gynaecology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| | - Eva Castella
- Department of Pathology, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain;
| | - Marta Piñol
- Department of General Surgery, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (D.P.); (F.G.-C.); (M.P.)
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
| | - Bonaventura Clotet
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- School of Medicine, Universitat Autónoma de Barcelona (UAB), Edifici M, Av. de Can Domènech, Bellaterra, 08193 Barcelona, Spain
- Retrovirology Laboratory IrsiCaixa Foundation, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| | - Sebastià Videla
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- Department of Clinical Pharmacology, Bellvitge University Hospital/IDIBELL/University of Barcelona, Hospitalet de Llobregat, Gran Via de les Corts Catalanes 199–203, 08907 Barcelona, Spain
- Correspondence: (J.C.); (S.V.)
| | - Guillem Sirera
- Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain; (B.R.); (A.C.); (C.L.); (A.T.); (B.C.); (G.S.)
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, Badalona, 08916 Barcelona, Spain
| |
Collapse
|
13
|
Revollo B, Tebe C, Peñafiel J, Blanco I, Perez-Alvarez N, Lopez R, Rodriguez L, Ferrer J, Ricart P, Moret E, Tural C, Carreres A, Matllo J, Videla S, Clotet B, Llibre JM. Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers. J Antimicrob Chemother 2021; 76:827-829. [PMID: 33219675 PMCID: PMC7717339 DOI: 10.1093/jac/dkaa477] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 10/27/2020] [Indexed: 11/29/2022] Open
Affiliation(s)
- Boris Revollo
- Division of Infectious Diseases and FLS Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias, Badalona, Spain
| | - Cristian Tebe
- Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Judith Peñafiel
- Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Ignacio Blanco
- Metropolitana Nord Laboratory, Institut Català de la Salut, Badalona, Spain
| | - Nuria Perez-Alvarez
- Division of Infectious Diseases and FLS Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias, Badalona, Spain
- Statistics and Operations Research Department, Universitat Politècnica de Catalunya-Barcelona Tech, Barcelona, Spain
| | - Ruth Lopez
- Occupational Risk Prevention Unit, University Hospital Germans Trias, Badalona, Spain
| | - Laura Rodriguez
- Pulmonary Medicine, University Hospital Germans Trias, Badalona, Spain
| | - Josep Ferrer
- Internal Medicine Department, University Hospital Germans Trias, Badalona, Spain
| | - Pilar Ricart
- Intensive Care Unit Division, University Hospital Germans Trias, Badalona, Spain
| | - Enrique Moret
- Anaesthesiology Department, University Hospital Germans Trias, Badalona, Spain
| | - Cristina Tural
- Internal Medicine Department, University Hospital Germans Trias, Badalona, Spain
| | - Anna Carreres
- Emergency Department, University Hospital Germans Trias, Badalona, Spain
| | - Joan Matllo
- Occupational Risk Prevention Unit, University Hospital Germans Trias, Badalona, Spain
| | - Sebastià Videla
- Division of Infectious Diseases and FLS Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias, Badalona, Spain
- Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital/Bellvitge Biomedical Research Institute (IDIBELL)/University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
| | - Bonaventura Clotet
- Division of Infectious Diseases and FLS Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias, Badalona, Spain
- Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain
- Universitat Autònoma de Barcelona, Bellaterra, Spain
| | - Josep M Llibre
- Division of Infectious Diseases and FLS Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias, Badalona, Spain
| |
Collapse
|
14
|
Pujantell M, Badia R, Galván-Femenía I, Garcia-Vidal E, de Cid R, Alcalde C, Tarrats A, Piñol M, Garcia F, Chamorro AM, Revollo B, Videla S, Parés D, Corral J, Tural C, Sirera G, Esté JA, Ballana E, Riveira-Muñoz E. ADAR1 function affects HPV replication and is associated to recurrent human papillomavirus-induced dysplasia in HIV coinfected individuals. Sci Rep 2019; 9:19848. [PMID: 31882741 PMCID: PMC6934649 DOI: 10.1038/s41598-019-56422-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 12/11/2019] [Indexed: 12/18/2022] Open
Abstract
Infection by human papillomavirus (HPV) alters the microenvironment of keratinocytes as a mechanism to evade the immune system. A-to-I editing by ADAR1 has been reported to regulate innate immunity in response to viral infections. Here, we evaluated the role of ADAR1 in HPV infection in vitro and in vivo. Innate immune activation was characterized in human keratinocyte cell lines constitutively infected or not with HPV. ADAR1 knockdown induced an innate immune response through enhanced expression of RIG-I-like receptors (RLR) signaling cascade, over-production of type-I IFNs and pro-inflammatory cytokines. ADAR1 knockdown enhanced expression of HPV proteins, a process dependent on innate immune function as no A-to-I editing could be identified in HPV transcripts. A genetic association study was performed in a cohort of HPV/HIV infected individuals followed for a median of 6 years (range 0.1-24). We identified the low frequency haplotype AACCAT significantly associated with recurrent HPV dysplasia, suggesting a role of ADAR1 in the outcome of HPV infection in HIV+ individuals. In summary, our results suggest that ADAR1-mediated innate immune activation may influence HPV disease outcome, therefore indicating that modification of innate immune effectors regulated by ADAR1 could be a therapeutic strategy against HPV infection.
Collapse
Affiliation(s)
- Maria Pujantell
- AIDS Research Institute-IrsiCaixa, Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Roger Badia
- AIDS Research Institute-IrsiCaixa, Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Iván Galván-Femenía
- Genomes for Life-GCAT Lab Group - Program of Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Edurne Garcia-Vidal
- AIDS Research Institute-IrsiCaixa, Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Rafael de Cid
- Genomes for Life-GCAT Lab Group - Program of Predictive and Personalized Medicine of Cancer (PMPPC), Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Carmen Alcalde
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Antonio Tarrats
- Department of Gynecology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Marta Piñol
- Department of Surgery, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Francesc Garcia
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Ana M Chamorro
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Boris Revollo
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Sebastian Videla
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - David Parés
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Javier Corral
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Cristina Tural
- Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Guillem Sirera
- Fundació Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain
| | - José A Esté
- AIDS Research Institute-IrsiCaixa, Badalona, Spain.
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain.
| | - Ester Ballana
- AIDS Research Institute-IrsiCaixa, Badalona, Spain.
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain.
| | - Eva Riveira-Muñoz
- AIDS Research Institute-IrsiCaixa, Badalona, Spain
- Health Research Institute Germans Trias i Pujol (IGTP), Badalona, Spain
| |
Collapse
|
15
|
Blanch-Lombarte O, Gálvez C, Revollo B, Jiménez-Moyano E, Llibre JM, Manzano JL, Boada A, Dalmau J, E. Speiser D, Clotet B, G. Prado J, Martinez-Picado J. Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. J Clin Med 2019; 8:jcm8122089. [PMID: 31805700 PMCID: PMC6947580 DOI: 10.3390/jcm8122089] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 11/14/2019] [Accepted: 11/22/2019] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8+ T cells. It is thought that PD-1 blockade could contribute to reinvigorate antiviral immunity and reduce the HIV-1 reservoir. METHODS Upon metastatic melanoma diagnosis, an HIV-1-infected individual on stable suppressive antiretroviral regimen was treated with pembrolizumab. A PET-CT was performed before and one year after pembrolizumab initiation. We monitored changes in the immunophenotype and HIV-1 specific-CD8+ T-cell responses during 36 weeks of treatment. Furthermore, we assessed changes in the viral reservoir by total HIV-1 DNA, cell-associated HIV-1 RNA, and ultrasensitive plasma viral load. RESULTS Complete metabolic response was achieved after pembrolizumab treatment of metastatic melanoma. Activated CD8+ T-cells expressing HLA-DR+/CD38+ transiently increased over the first nine weeks of treatment. Concomitantly, there was an augmented response of HIV-1 specific-CD8+ T cells with TNF production and poly-functionality, transitioning from TNF to an IL-2 profile. Furthermore, a transient reduction of 24% and 32% in total HIV-1 DNA was observed at weeks 3 and 27, respectively, without changes in other markers of viral persistence. CONCLUSIONS These data demonstrate that pembrolizumab may enhance the HIV-1 specific-CD8+ T-cell response, marginally affecting the HIV-1 reservoir. A transient increase of CD8+ T-cell activation, TNF production, and poly-functionality resulted from PD-1 blockade. However, the lack of sustained changes in the viral reservoir suggests that viral reactivation is needed concomitantly with HIV-1-specific immune enhancement.
Collapse
Affiliation(s)
- Oscar Blanch-Lombarte
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
- Autonomous University of Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain;
| | - Cristina Gálvez
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
- Autonomous University of Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain;
| | - Boris Revollo
- Infectious Diseases Department, University Hospital “Germans Trias i Pujol”, 08916 Badalona, Spain; (B.R.); (J.M.L.)
| | - Esther Jiménez-Moyano
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
| | - Josep M. Llibre
- Infectious Diseases Department, University Hospital “Germans Trias i Pujol”, 08916 Badalona, Spain; (B.R.); (J.M.L.)
| | - José Luís Manzano
- Medical Oncology Service—Badalona Applied Research Group in Oncology (B-ARGO Group), University Hospital “Germans Trias i Pujol”—Catalan Insitute of Oncology (ICO), 08916 Badalona, Spain;
| | - Aram Boada
- Autonomous University of Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain;
- Department of Dermatology, University Hospital “Germans Trias i Pujol”, 08916 Badalona, Spain
| | - Judith Dalmau
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
| | - Daniel E. Speiser
- Department of Oncology, University of Lausanne, CH-1015 Lausanne, Switzerland
| | - Bonaventura Clotet
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
- Autonomous University of Barcelona, 08193 Cerdanyola del Vallès, Barcelona, Spain;
- Infectious Diseases Department, University Hospital “Germans Trias i Pujol”, 08916 Badalona, Spain; (B.R.); (J.M.L.)
- Chair in Infectious Diseases and Immunity, Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain
| | - Julia G. Prado
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
- Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
- Correspondence: (J.G.P.); (J.M.-P.)
| | - Javier Martinez-Picado
- IrsiCaixa AIDS Research Institute, 08916 Badalona, Spain; (O.B.-L.); (C.G.); (E.J.-M.); (J.D.); (B.C.)
- Chair in Infectious Diseases and Immunity, Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), 08500 Vic, Spain
- Germans Trias i Pujol Research Institute (IGTP), 08916 Badalona, Spain
- Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
- Correspondence: (J.G.P.); (J.M.-P.)
| |
Collapse
|
16
|
Revollo B, Videla S, Sirera G, García-Cuyás F, Parés D, Corral J, Clotet B, Llibre JM. Natural History of Anal Squamous Intraepithelial Lesions in HIV-Positive Men with Normal Baseline Cytology. AIDS Patient Care STDS 2019; 33:459-465. [PMID: 31682165 DOI: 10.1089/apc.2019.0186] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The natural history of squamous intraepithelial lesions (SILs) in the anal canal of HIV-infected men is incompletely understood. We assessed the incidence and factors associated with SIL and invasive anal squamous cell carcinoma (IASCC) among HIV-infected men with normal cytology at baseline. We performed a single-center prospective cohort study [men who have sex with men (MSM) and men who have sex with women (MSW)]. The incidence of anal canal SIL (low grade and high grade) and IASCC were estimated and predictive factors analyzed. The study population comprised 297 HIV-infected men with a normal cytology result and no anal human papillomavirus (HPV)-related diseases. Of these, 251 (85%) had at least one evaluable set of cytology data during follow-up (172 MSM, 79 MSW). The median follow-up time was 4 years. The cumulative incidence of SIL was 43% (107/251): 52% in MSM (90/172) and 22% in MSW (17/79), p < 0.0001. The incidence rate of SILs was 109 (95% confidence interval = 90-132) per 1000 person-years: 142 in MSM and 49 in MSW, p < 0.0001. HPV infection, receiving antiretroviral treatment (ART), and being MSM were independently associated risk factors. The incidence of IASCC was 0.15 per 1000 person-years among MSM and 0 in MSW. HIV-infected men, both MSM and MSW, are at high risk of developing SIL despite having a normal anal cytology at baseline. The incidence of anal canal SIL was higher among MSM, but was also remarkable among MSW. Independent risk factors associated with SIL were being HIV-infected MSM at high risk for acquisition of STIs, time on ART, and HPV infection.
Collapse
Affiliation(s)
- Boris Revollo
- Lluita Contra La SIDA Foundation, Barcelona, Catalonia, Spain
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Catalonia, Spain
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| | - Sebastián Videla
- Lluita Contra La SIDA Foundation, Barcelona, Catalonia, Spain
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Catalonia, Spain
- Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
- Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
- University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
| | - Guillem Sirera
- Lluita Contra La SIDA Foundation, Barcelona, Catalonia, Spain
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Catalonia, Spain
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| | - Francesc García-Cuyás
- Department of Surgery, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| | - David Parés
- Department of Surgery, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| | - Javier Corral
- Department of Surgery, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| | - Bonaventura Clotet
- Lluita Contra La SIDA Foundation, Barcelona, Catalonia, Spain
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Catalonia, Spain
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
- Retrovirology Laboratory IrsiCaixa Foundation, Barcelona, Catalonia, Spain
| | - Josep M Llibre
- Lluita Contra La SIDA Foundation, Barcelona, Catalonia, Spain
- Department of Medicine, Autonomous University of Barcelona, Barcelona, Catalonia, Spain
- Infectious Diseases Department, Germans Trias i Pujol University Hospital, Barcelona, Catalonia, Spain
| |
Collapse
|
17
|
Abstract
In reference to the interesting article published by Silva et al., we believe it is important to comment on some aspects related to anal cytology as a tool for the screening of anal intraepithelial neoplasia (AIN) in at risk patients.
Collapse
Affiliation(s)
| | | | - David Parés
- Colorectal Service, Barts NHS Trust, United Kingdom
| |
Collapse
|
18
|
Vela S, Videla S, Ornelas A, Revollo B, Clotet B, Sirera G, Piñol M, García-Cuyás F. Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men. PLoS One 2018; 13:e0199033. [PMID: 30067738 PMCID: PMC6070186 DOI: 10.1371/journal.pone.0199033] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Accepted: 05/30/2018] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND There is limited information on the effectiveness of available treatments for anal condyloma acuminata in HIV-1-infected men. AIM To provide data on the effectiveness of electrosurgical excision, infrared coagulation and pharmacological (imiquimod) treatments for anal condyloma acuminata (peri-anal and/or intra-anal) in HIV-1-infected men based on authors' practice. METHODS Single-center, retrospective descriptive analysis of HIV-1-infected men, 18 years or older treated for anal condyloma acuminata. Standard treatments were offered: electrosurgery excision, infrared coagulation and topical imiquimod. Effectiveness was evaluated by the recurrence rate at 1 year after treatment. Recurrence was defined as any anal condyloma acuminata diagnosed after 3 months of condyloma-free survival post-treatment. Anal cytology and human-papillomavirus-infection (HPV) was assessed. RESULTS Between January 2005 and May 2009, 101 men were treated for anal condyloma acuminata: 65 (64%) with electrosurgery, 27 (27%) with infrared coagulation and 9 (9%) with imiquimod. At 1 year after treatment, the cumulative recurrence rate was 8% (4/65, 95%CI: 2-15%) with electrosurgery excision, 11% (3/27, 95%CI: 4-28%) with infrared coagulation and 11% (1/9, 95%CI: 2-44%) with imiquimod treatment. No predictive factors were associated with recurrence. Anal HPV-6 or HPV-11 was detectable in 98 (97%) patients and all had high-risk HPV genotypes, and 89 (88%) patients had abnormal anal canal cytology. Limitations: this was a retrospective descriptive analysis; limited to a single center; it cannot know if the recurrence is related to new infection. CONCLUSION Recurrence of anal condyloma after any treatment was common. Abnormal anal cytology and high-risk HPV-infection were highly prevalent in this population, therefore at high-risk of anal cancer, and warrants careful follow-up.
Collapse
Affiliation(s)
- Sandra Vela
- Department of Surgery, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Sebastian Videla
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- Department of Clinical Pharmacology, University Hospital Bellvitge / IDIBELL / Barcelona University, Hospitalet de Llobregat, Barcelona, Catalonia, Spain
- * E-mail: , ,
| | - Arelly Ornelas
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Boris Revollo
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Bonaventura Clotet
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- Retrovirology Laboratory IrsiCaixa Foundation, Badalona, Catalonia, Spain
| | - Guillem Sirera
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Marta Piñol
- Department of Surgery, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| | - Francesc García-Cuyás
- Department of Surgery, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
- Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain
| |
Collapse
|
19
|
Loste C, Revollo B, Puyalto P, Cuadras P, Carrato C, Llibre JM. A Fast Progressing, Space-Occupying Lesion on the Brain of an HIV-Infected Patient. AIDS Res Hum Retroviruses 2016; 32:770-1. [PMID: 27408993 DOI: 10.1089/aid.2015.0372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Cora Loste
- Department of Internal Medicine, Hospital General de Vic, Vic, Spain
| | - Boris Revollo
- HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
- Fundació lluita contra la Sida, Badalona, Spain
| | - Paloma Puyalto
- HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
- Universitat Internacional de Catalunya, Barcelona, Spain
| | - Patricia Cuadras
- HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Cristina Carrato
- HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Josep Maria Llibre
- HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
- Fundació lluita contra la Sida, Badalona, Spain
| |
Collapse
|
20
|
Nevot M, Boesecke C, Parera M, Andrés C, Franco S, Revollo B, Ingiliz P, Tural C, Clotet B, Rockstroh JK, Martinez MA. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. J Viral Hepat 2014; 21:e19-28. [PMID: 24674023 DOI: 10.1111/jvh.12254] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The growing number of cases of acute hepatitis C (AHC) infections among human immunodeficiency virus type 1 (HIV-1)-positive men who have sex with men (MSM) in the last 10 years has promoted the search for predictors of AHC clearance as well as for epidemiological networks of viral transmission. We characterized the diversity and catalytic efficiency of HCV NS3/4A protease quasispecies in AHC patients coinfected with HIV-1. Plasma samples obtained at HCV diagnosis from 18 MSM HIV-coinfected patients with AHC were studied. Five HCV monoinfected patient samples with AHC were also investigated. An average of 39 clones from each sample was analysed. The catalytic efficiency of the dominant quasispecies (i.e. the most abundant) from each quasispecies was also assayed for mitochondrial antiviral signalling protein (MAVS) cleavage. Phylogenetic analysis identified two clusters of patients with highly related viruses, suggesting a common source of HCV infection. None of the 18 MSM HIV-coinfected patients spontaneously cleared HCV, although 78% of the treated patients achieved a sustained virological response after early treatment with pegylated interferon (pegIFN) plus ribavirin (RBV). The synonymous-nonsynonymous (ds/dn) mutation ratio, a marker of selective pressure, was higher in AHC compared to 26 HIV-1-infected men with genotype 1a chronic hepatitis C (CHC) (P < 0.0001). NS3/4A proteases from AHC patients also exhibited higher catalytic efficiency compared to CHC patients (P < 0.0001). No differences were found when ds/dn mutation ratios and NS3/4A protease catalytic efficiencies from AHC HIV-coinfected patients were compared with AHC monoinfected patients. The presence of epidemiological networks of HCV transmission was confirmed among HIV-1-positive MSM. In addition, substantial genetic diversity was demonstrated in AHC. NS3/4A protease efficiency cleaving MAVS may be associated with virus transmission and response to pegIFN/RBV treatment.
Collapse
Affiliation(s)
- M Nevot
- Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Llibre JM, Revollo B, Vanegas S, Lopez-Nuñez JJ, Ornelas A, Marin JM, Santos JR, Marte P, Morera M, Zuluaga P, Tor J, Clotet B. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries. ACTA ACUST UNITED AC 2013; 45:635-44. [DOI: 10.3109/00365548.2013.777778] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|